Bayesian hierarchical EMAX model for dose‐response in early phase efficacy clinical trials
Byron J. Gajewski(University of Kansas Medical Center), Renee Martin(Medical University of South Carolina), Scott Berry(Queen's University), William G. Barsan, Gaylan L. Rockswold(Hennepin County Medical Center), Caitlyn Meinzer(Medical University of South Carolina), Frederick K. Korley(University of California, San Francisco)
Cited by 20
Related Papers
Derivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis
|JAMA|2019|1.5k
Comparison of Antiarrhythmic Drug Therapy and Radiofrequency Catheter Ablation in Patients With Paroxysmal Atrial Fibrillation
|JAMA|2010|1.2k
Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke
|New England Journal of Medicine|2013|980
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
|Alzheimer s Research & Therapy|2021|818